Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 13/20 | 0.77 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.77 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.60 |
| ▸ | CA1 | P00915 | 6/20 | 0.46 |
| ▸ | CA2 | P00918 | 6/20 | 0.46 |
| ▸ | CA7 | P43166 | 4/20 | 0.46 |
| ▸ | CA12 | O43570 | 4/20 | 0.46 |
| ▸ | CA9 | Q16790 | 4/20 | 0.46 |
| ▸ | CA4 | P22748 | 3/20 | 0.46 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.46 |
| ▸ | CA3 | P07451 | 1/20 | 0.46 |
| ▸ | CA6 | P23280 | 1/20 | 0.46 |
| ▸ | CA5A | P35218 | 1/20 | 0.46 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.46 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6486425 | 1.00 | PTGS2 (0.77) | PTGS2PTGS1ALOX5CA1CA2 | |
| SCHEMBL6291354 | 0.81 | PTGS2 (0.68) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6476564 | 0.81 | PTGS2 (0.68) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6476911 | 0.76 | PTGS2 (0.51) | PTGS2PTGS1CA1CA2CA7 | |
| SCHEMBL6476634 | 0.76 | PTGS2 (0.51) | PTGS2PTGS1CA1CA2CA7 | |
| SCHEMBL6484222 | 0.75 | PTGS2 (1.00) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6477322 | 0.74 | PTGS2 (1.00) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6476960 | 0.74 | PTGS2 (1.00) | PTGS2PTGS1ALOX5 | |
| SCHEMBL6475771 | 0.72 | PTGS2 (0.49) | PTGS2PTGS1ALOX5CA1CA2 | |
| SCHEMBL6477030 | 0.72 | PTGS2 (0.49) | PTGS2PTGS1ALOX5CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936632-B2 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | MERCKLE GMBH (DE) | 2005-08-30 | — | — | US | disclosed |
| US-20040122002-A1 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | MERCKLE GMBH (DE) | 2004-06-24 | — | — | US | disclosed |
| EP-1246825-B1 | FUSED PYRROLE COMPOUNDS, PHARMACEUTICAL AGENTS CONTAINING THE SAME, AND THE USE THEREOF | MERCKLE GMBH (DE) | 2003-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040122002-A1 | Fused pyrrole compounds, pharmaceutical agents containing the same, and the use thereof | PTGS1, PTGS2, PTGER1 | PTGS2 2/4885PTGS1 1/4885ALOX5 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.